| Literature DB >> 34143380 |
Cato T Laurencin1,2,3,4,5,6,7, Hannah Valantine8,9, Clyde Yancy8,10,11, Camara Phyllis Jones8,12,13,14,15, Cedric Bright8,16.
Abstract
Established in 2019, the Roundtable on Black Men and Black Women in STEM convenes a broad array of stakeholders that focus on the barriers and opportunities encountered by Black men and Black women as they navigate the pathways from K-12 and postsecondary education to careers in science, engineering, and medicine. Through meetings, public workshops, and publications, the Roundtable advances discussions that raise awareness and/or highlight promising practices for increasing the representation, retention, and inclusiveness of Black men and Black women in STEM. In keeping with the charge of the Roundtable, Roundtable leadership and leaders of the COVID-19 action group conducted an informational video in January 2021 to provide an in-depth discussion around common, justified questions in the Black community pertaining to the COVID-19 vaccine. The manuscript addresses selected questions and answers relating to the different types of COVID-19 vaccines and their development, administration, and effectiveness. Discussion focuses on addressing vaccine misconceptions, misinformation, mistrust, and hesitancy; challenges in prioritizing vaccinations in diverse populations and communities; dealing with racism in medicine and public health; optimizing communication and health education; and offering practical strategies and recommendations for improving vaccine acceptance by clinicians, health care workers, and the Black community. This manuscript summarizes the content in the YouTube video ( https://www.youtube.com/watch?v=wdEC9c48A_k ).Entities:
Keywords: Black; Community; Covid-19; Hesitancy; Roundtable; Vaccine
Mesh:
Substances:
Year: 2021 PMID: 34143380 PMCID: PMC8212792 DOI: 10.1007/s40615-021-01082-9
Source DB: PubMed Journal: J Racial Ethn Health Disparities ISSN: 2196-8837
Fig. 1Efficacy of the Pfizer vaccine (BNT162b2) against COVID-19 after the first dose. Data shown represents the cumulative incidence of COVID-19 after the first dose. Blue line represents individuals who received placebo. Red line indicates individuals that received the vaccine (BNT162b2) [5]
Demographic characteristics of the participants in the Pfizer vaccine clinical trial [5]
*Percentages may not total 100 because of rounding
†Race of ethnic group was reported by the participants
‡The body mass index is the weight in kilograms divided by the square of the height in meters
Pfizer vaccine efficacy overall and by subgroup [5]
*Surveillance time is the total time in 1000 person-years for the given end point across all participants within each group at risk for the end point. The time period for COVID-19 case accrual is from 7 days after the second dose to the end of the surveillance period
†The confidence interval for vaccine efficacy is derived according to the Clopper-Pearson model, adjusted for surveillance time
‡Race or ethnic group was reported by the participants. “All others” included the following categories: American Indian or Alaskan Native, Asian, Native Hawaiian or other Pacific Islander, multiracial, and not reported